Trupanion, Inc. filed its Form 10-Q with the SEC on November 5, 2026, covering the quarterly period ended September 30, 2026, reporting revenue growth and net income for both the three- and nine-month periods.
Key Highlights
- Quarterly revenue: $405,593 thousand for the three months ended September 30, 2026, compared with $366,920 thousand in the same period of 2025, according to the filing.
- Net income: $9,282 thousand for the third quarter of 2026, up from $5,873 thousand in Q3 2025, as reported in the condensed consolidated statements of operations.
- Nine-month revenue: $1,182,576 thousand for the nine months ended September 30, 2026, versus $1,062,452 thousand for the same period in 2025.
- Diluted EPS: $0.21 per share for Q3 2026, compared with $0.13 per share for Q3 2025, the filing disclosed.
- Total assets: $921,619 thousand at September 30, 2026, against $915,044 thousand at December 31, 2025.
- Shares outstanding: approximately 43,265,932 shares of common stock as of October 29, 2026, per the cover page.
- Accumulated deficit reduced: from $206,455 thousand at December 31, 2025 to $185,462 thousand at September 30, 2026, reflecting the nine-month net income of $20,993 thousand.
Trupanion's Pet Insurance Business: Third-Quarter 2026 Financial Results
Trupanion, a Seattle-based provider of medical insurance for cats and dogs, reported quarterly revenue of $405,593 thousand for the three months ended September 30, 2026, according to the 10-Q filed with the Nasdaq-listed company (NASDAQ:TRUP) on November 5, 2026. Veterinary invoice expense, the primary cost tied to paying covered pet medical claims, totaled $287,458 thousand for the quarter, while other cost of revenue was $48,635 thousand, bringing total cost of revenue to $336,093 thousand.
Operating income for the third quarter of 2026 reached $9,543 thousand, compared with $5,859 thousand for the same period in 2025, the filing disclosed. New pet acquisition expense, which the company reports as a separate operating line item reflecting its subscriber-growth spending, was $24,179 thousand in Q3 2026 versus $21,946 thousand in Q3 2025. Technology and development expense rose to $12,511 thousand from $9,887 thousand in the prior-year quarter, while general and administrative expense increased to $19,440 thousand from $18,311 thousand.
On the balance sheet, the company reported cash and cash equivalents of $170,355 thousand and short-term investments of $226,482 thousand at September 30, 2026. Deferred revenue, which primarily represents premiums collected in advance from policyholders, stood at $290,155 thousand, up from $270,935 thousand at December 31, 2025. Long-term debt totaled $94,472 thousand, down from $101,784 thousand at year-end 2025. Treasury stock increased to $41,603 thousand, reflecting the repurchase of 1,858,575 shares at September 30, 2026, compared with 1,028,186 shares held in treasury at December 31, 2025. The filing noted that forward-looking statements contained in the report are subject to risks and uncertainties described in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
What Was Disclosed
Trupanion's 10-Q for the quarter ended September 30, 2026 reported $405,593 thousand in quarterly revenue, net income of $9,282 thousand, diluted earnings per share of $0.21, and total assets of $921,619 thousand, with the company classified as a large accelerated filer.



Please wait processing your request...